Comparing new MS therapies – Oral drugs
The medication options for multiple sclerosis (MS) have broadened considerably in recent years and at least two new drugs are expected to be approved in 2013. The table below summarizes the Phase III study results in relapsing-remitting MS that have been presented or published for oral MS drugs. (Infusion drugs will be summarized next week.) While results shouldn’t be directly compared because of differences in the people being studied, the side-by-side comparisons may help you in making the best treatment decision for your personal situation. All studies were for two years.
ORAL DRUGS
*Annualized relapse rate=number of relapses in the study population divided by number of years of study. E.g. ARR of 0.1=1 relapse every 10 years. **other side effects can occur. [] not statistically significant. †Safety monitoring requirements will be determined once the drug has been approved.
Share this article
Facebook Twitter pin it! Email
Related Posts
November 7, 2024New MS therapies in development: ECTRIMS 2024
October 25, 2024New research presented at MS congress: ECTRIMS 2024
August 22, 2024Benign or burned-out MS: do they exist?
June 25, 2024Q & A on contraception and MS: what the experts say
May 6, 20243 reasons for hope during MS Awareness Month
Back
